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Abstract
Azaspiracids (AZA) are polyether marine dinoflagellate toxins that accumulate in shellfish and
represent an emerging human health risk. Although human exposure is primarily manifested by
severe and protracted diarrhea, this toxin class has been shown to be highly cytotoxic, a teratogen
to developing fish, and a possible carcinogen in mice. Until now, AZA's molecular target(s) has
not yet been determined. Using three independent methods (voltage clamp, channel binding assay,
and thallium flux assay), we have for the first time demonstrated that AZA1, AZA2, and AZA3
each bind to and block the hERG (human ether-à-go-go related gene) potassium channel
heterologously expressed in HEK-293 mammalian cells. Inhibition of K+ current for each AZA
analogue was concentration-dependent (IC50 value range: 0.64 - 0.84 μM). The mechanism of
hERG channel inhibition by AZA1 was investigated further in Xenopus oocytes where it was
shown to be an open state-dependent blocker and, using mutant channels, to interact with F656 but
not with Y652 within the S6 transmembrane domain that forms the channel's central pore. AZA1,
AZA2, and AZA3 were each shown to inhibit [3H]dofetilide binding to the hERG channel and
thallium ion flux through the channel (IC50 value range: 2.1 – 6.6 μM). AZA1 did not block K+
current of the closely related EAG1 channel. Collectively, these data suggest that the AZAs
physically block the K+ conductance pathway of hERG1 channels by occluding the cytoplasmic
mouth of the open pore. Although the concentrations necessary to block hERG channels are
relatively high, AZA-induced blockage may prove to contribute to the toxicological properties of
the AZAs.
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Azaspiracids (AZAs) are polyether toxins produced by toxigenic species of Azadinium1, 2
that can accumulate in shellfish and cause human illness.3 Although there have been no
deaths associated with the AZA toxins, humans exposed to AZAs experience severe
gastrointestinal illness.4, 5 Over the past decade, extensive progress has been made on
elucidating the chemical structure of AZA and its various analogs. To date, over 20 naturally
occurring analogs of AZA have been described,6, 7 but thus far only AZA1, AZA2, and
AZA3 (Figure 1) appear to present a human health risk and are subject to food safety
regulations.8In vivo studies in mice exposed to AZA1 revealed severe effects such as
deformation of intestinal epithelial villi9, 10 as well as damage to T and B lymphocytes,
accumulation of fatty acid deposits in the liver, increased prevalence of lung tumors, and
hyperplasia within the stomach lining.11, 12In vitro studies have shown the AZAs to be
highly cytotoxic causing a variety of cytoskeletal effects13-18 and stimulation of cAMP
production and cytosolic calcium release.19, 20 In spinal cord neurons, AZA1 was shown to
inhibit bioelectrical activity through a mechanism that was independent of voltage-gated
sodium (Na+) or calcium (Ca2+) current.21 Recent findings suggest the AZAs cause
apoptosis,13, 22, 23 although this toxin class may have multiple molecular targets13, 14 and
also induce necrotic pathways concurrently.
To date, the mechanism(s) of action of the AZA toxin class has not been identified, but
during a series of preliminary activity screening assays wherein AZA1 was tested towards
various protein phosphatases, kinases, G-protein coupled receptors, and ion channels, there
was an indication that AZA1 had an adverse effect on a member of the ether-à-go-go (EAG)
K+ channel family. EAG K+ channels were first discovered in Drosophila where the eag
mutant was associated with spontaneous repetitive axon firing in motor neurons.24 It was
later determined that eag encodes a K+ channel subunit25 that functions to conduct a delayed
rectifier K+ current.26 A human homolog (hEAG) of Drosophila eag and a related gene
(hERG, human ether-à-go-go related gene) were later discovered in a human hippocampus
cDNA library.27 hERG K+ channels are transcriptionally expressed in a broad array of cell/
tissue types including heart (differentially expressed across the 4 chambers), brain, liver,
kidney, breast, pancreas, and colon with the highest levels of expression in heart and brain
tissue.28 Expression is cell cycle dependent, involved in apoptosis,29 and commonly up-
regulated in cancerous cells.30
The hERG (aka KCNH2) encodes the pore forming α subunit of the voltage-gated
potassium channel Kv11.1.27 The channel consists of four α subunits, each with six
transmembrane domains (S1-S6) where S5 and S6 form the channel's central pore. In the
heart, hERG proteins coassemble to form the channel that conducts the rapid delayed
rectifier K+ current (IKr), which is critical for the repolarization phase of the cardiac action
potential.31 Mutations in this channel have been associated with congenital long (and short)
QT syndromes, characterized by prolonged (and shortened) ventricular repolarization and
increased risk of fatal cardiac arrhythmia. The hERG channel has been shown to be the
target for class III antiarrhythmic drugs such as dofetilide, which can reduce the risk of re-
entrant arrhythmias by prolonging the action potential duration and refractory period without
slowing conduction velocity in the myocardium. However, block of this channel by class III
agents and numerous noncardiac drugs with poor predictability based on structure, can also
cause excessive prolongation of QT intervals and induce arrhythmia (“acquired long QT
syndrome”). Due to the wide spectrum of compounds that can block hERG channels and
induce arrhythmia, drug regulatory agencies have issued recommendations for the
evaluation of hERG activity in the early preclinical stages of drug development.
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A variety of natural toxins are known to target hERG channels,32 including but not limited
to scorpion venoms,33 spider venoms,34 sea anemone toxins,35 and the algal toxins
ciguatoxin,36 and gambierol.37 The aim of the current study was to examine the effects of




The AZAs were isolated from cooked mussel tissue (M. edulis) collected in 2005 from
Bruckless, Donegal, Ireland. The toxins were purified using a 7-step protocol as outlined by
Kilcoyne et al.38 and stored at -20 °C in methanol. Purity (>95%) was confirmed by LC-MS/
MS and NMR spectroscopy. For experimental use, the AZAs were dried down under N2 gas
and resuspended in DMSO.
Mammalian cell voltage clamp protocols and data analysis
HEK-293 cells stably transfected with hERG cDNA (GenScript Inc., Piscataway, NJ, USA)
were regularly subcultured in Dulbecco's Modified Eagle Medium supplemented with 10%
fetal bovine serum and 200 μg/mL G418 antibiotic (cat. #G8168, Sigma-Aldrich, St. Louis,
MO, USA). HEK-293 cells expressing hERG were plated in 35 mm dishes at least 24 h prior
to the day of experiment and maintained at 37 °C/5% CO2. The extracellular solution for
whole cell patch clamp recordings was composed of (in mM): 137 NaCl; 1.2 MgCl2; 5.4
KCl; 10 glucose; 10 HEPES; and 2 CaCl2. pH was adjusted to 7.4 with NaOH. The
osmolarity was adjusted to 305 mOsm with sucrose. The intracellular solution for whole cell
patch clamp recordings was composed of (in mM): 140 KCl; 1 MgCl2; 5 EGTA; 10 HEPES
and 5 Na2ATP. The pH was adjusted to 7.2 with KOH. The osmolarity was adjusted to 295
mOsm with sucrose.
For electrophysiology recordings, micropipettes were pulled from borosilicate glass that had
a tip resistance of 3 - 5 MΩ when filled with intracellular solution. For each experiment, a
single dish of cells was removed from the incubator, washed twice with room temperature
(RT) extracellular solution and then placed on the microscope stage. A commercial patch
clamp amplifier was used for the whole cell recordings. The tail currents were evoked at RT
once every 30 s by a 3 s -50 mV repolarizing pulse following a 2 s +50 mV depolarizing test
pulse. The holding potential was -80 mV and a 50 ms pulse to -50 mV preceded each test
pulse and served as a baseline for calculating the amplitude of the peak tail current. Only
stable cells with recording parameters above threshold were subjected to AZA exposure.
The hERG channel currents were allowed to stabilize over a 3 min period in the presence of
vehicle alone prior to AZA addition. The cells were kept in the test solution until the peak
tail current was stable (< 5% change) for ~5 sweeps or for a maximum of 6 min, whichever
came first. Criteria for acceptance of measurements were (i) whole-cell membrane resistance
(Rm) was greater than 1,000 MΩ throughout the experiment, (ii) initial tail current was
greater than 300 pA, (iii) series resistance value following establishment of whole-cell mode
was less than 12 MΩ, and (iv) the leak current that the cell began with or developed over
time was less than 10% of the ionic current magnitude (up to a maximum of 80 pA). The
hERG channel antagonist terfenadine (cat. #T9652, Sigma-Aldrich, St. Louis, MO, USA)
was used as a positive control. All test agent stock solutions were resuspended in DMSO
and diluted in extracellular solution. DMSO additions never exceeded 0.3% vol./vol. which
itself did not affect hERG currents (data not shown).
Voltage clamp data were recorded by Clampex (version 10.1) and data acquisition and
analyses were performed using pCLAMP (version 10.1; Molecular Devices, CA, USA) and
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Origin 8 (OriginLab Corp., MA, USA). Peak tail amplitudes were plotted as a function of
the sweep number. Five peak tail current measurements at the steady state AZA addition
were averaged and used as the control current amplitude. Four or five peak tail current
measurements at the steady state after AZA addition were averaged and used as the
remaining current amplitude after inhibition by AZA. The % inhibition of hERG channel
due to AZA was calculated from the following equation: % inhibition = (1- (remaining
current amplitude) / (control current amplitude)) × 100. Unless stated differently, all data are
presented as means ± SEM of at least three independent experiments. IC50 and 95%
confidence interval determinations were calculated using four parameter, non-linear
regression analysis (GraphPad Prism, ver. 5.0c, San Diego, CA, USA).
Heterologous expression of ERG channels in oocytes
Human ERG1 cDNA (KCNH2; GenBank accession no. NP_000229) was cloned into the
pSP64 oocyte expression vector. Two hERG channel mutants (Y652A and F656T), chosen
because of the known sites that have been shown to attenuate block by many drugs,39-41
were introduced using the QuikChange mutagenesis kit (Agilent Technologies, Santa Clara,
CA, USA) and verified by DNA sequence analyses. hERG1 plasmids were linearized with
EcoR1 and cRNA was prepared by in vitro transcription with mMessage mMachine SP6 kit
(Ambion, Austin, TX, USA) after linearization of plasmids with EcoR1. Human EAG1
cDNA (KCNH1; GenBank accession no. AJ001366.1) cloned into psGEMHE oocyte
expression vector was kindly provided by the late Dr. Dennis Wray. hEAG1 plasmids were
linearized by NotI and cRNA was prepared with the mMessage mMachine T7 kit (Ambion,
Austin, TX, USA). The concentration of cRNA was quantified using a RiboGreen assay
(Life Technologies, Grand Island, NY, USA).
Oocyte isolation and cRNA injection
The procedures used to harvest oocytes from Xenopus laevis were approved by the
University of Utah Institutional Animal Care and Use Committee. Briefly, frogs were
anesthetized with 0.2% tricaine methane sulfonate before removal of ovarian lobes that were
then manually dispersed with forceps, then treated for 90–120 min with 1 mg/mL of type II
collagenase (Worthington Biochemical Corp., Lakewood, NJ, USA) in a Ca2+-free solution
containing (in mM): 96 NaCl, 2 KCl, 1 MgCl2, and 5 HEPES; pH 7.6. Stage IV and V
oocytes were injected with ~5 ng (hERG1) or ~0.2 ng (hEAG1) wild-type (WT) or mutant
cRNA per oocyte and incubated for 2-3 days at 18 °C in Barth's saline solution before use in
voltage clamp experiments. Barth's solution contained (in mM): 88 NaCl, 2 KCl, 0.41
CaCl2, 0.33 Ca(NO3)2, 1 MgSO4, 2.4 NaHCO3, 10 HEPES, 1 pyruvate, 50 mg/L
gentamycin; pH 7.4.
Oocyte two-electrode voltage clamp protocols and data analysis
Ionic currents were recorded at 22–24 °C from single Xenopus oocytes using a standard
two-microelectrode voltage clamp technique42, 43 using a GeneClamp 500 amplifier, and
Digidata 1322A data acquisition system controlled by pCLAMP 8.2 software (Molecular
Devices, Inc., Sunnyvale, CA, USA). Oocytes were placed in a static, small volume (75 μL)
recording chamber. The bathing solution contained (in mM): 98 NaCl, 2 KCl, 1 CaCl2, 1
MgCl2, 5 HEPES; pH 7.6. Agarose-cushion microelectrodes were fabricated as described 44
and had tip resistances of 0.4 – 0.6 MΩ when back-filled with 3 M KCl.
During an initial equilibration period, oocytes were voltage clamped to a holding potential
of –80 mV, and 1-s pulses to a test potential (Vt) of 0 mV were applied every 10 s until
current magnitude reached a steady-state level. The current-voltage (I-Vt) relationships for
hERG1 or hEAG1 channels were determined by applying 2-s pulses to test potentials
ranging from –70 to +40 mV in 10 mV increments. The holding potential was –80 mV and
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tail currents were elicited at –70 mV. Conductance-voltage (G-Vt) relationships for hERG1
were determined by tail current analysis. Peak outward tail currents were normalized to their
maximum value (at +40 mV) and plotted as a function of test potential. The resulting plot
was fitted to a Boltzmann function (Eq. 1):
(1)
where V0.5 is the half-point of activation and k is the slope factor. The G-V relationship for
hEAG1 channels was determined by analysis of test pulse currents. The outward current at
the end of 2-s pulses (Ipeak) was divided by the electrical driving force, test voltage minus
reversal potential (Vt – Erev). The resulting relationship was fitted to a Boltzmann function
and extrapolated to more positive potentials to estimate the maximum current (Imax) under
control conditions. The G/Gmax for each oocyte was then estimated as Ipeak/Imax. The time-
dependent decay of hERG1 tail currents elicited at –70 mV after activation pulses to +40 to
0 mV were fitted to a bi-exponential function (Levenberg-Marquardt method) to determine
the time constants for channel deactivation.
After obtaining baseline recordings, a small aliquot of AZA1 stock solution (500 μM in
10% DMSO) was added directly to the bathing solution to obtain the final desired toxin
concentration. During the onset of AZA1 action, 1 s pulses to a Vt of 0 mV were applied
every 10 s until a new steady-state current level was achieved. The I-Vt relationship protocol
was then repeated in the presence of AZA1.
Off-line data analysis was performed with Clampfit 8.2 (Molecular Devices, CA, USA),
Origin 8.5 (OriginLab, MA, USA) and Excel (Microsoft Corp., WA, USA) software. Data
are expressed as mean ± SEM (n = number of oocytes).
hERG channel binding assay
The hERG channel binding assay was performed as described by Huang et al.45 Briefly,
membranes were prepared from hERG-expressing HEK-293 cells and competition assays
were performed in 96-well plates using [3H]dofetilide (1.5 nM) in hERG binding buffer
(hBB) containing (in mM): 135 NaCl, 5 KCl, 0.8 MgCl2, 10 HEPES, 10 glucose, 1 EGTA,
and 0.01% BSA, pH 7.4. The AZA test compounds were diluted in hBB from 500 μM stock
solutions in 10% DMSO / PBS (pH 7.4). Radioactivity retained on glass fiber filters was
counted on a Perkin Elmer 1450 Microbeta Trilux plate counter and data are presented as
disintegrations per minute (dpm). Dofetilide was used as a positive control. All data are
presented as means ± SEM of three replicate wells. IC50 and 95% confidence interval
determinations were calculated using four parameter, non-linear regression analysis
(GraphPad Prism, ver. 5.0c, CA, USA). Data (dpm per well) were also analyzed by non-
linear regression, one-site saturation binding (GraphPad Prism) to obtain Ki values for each
AZA analogue according to the Cheng-Prusoff equation.46 An experimentally determined
Kd value of 4.7 nM was used for [3H]dofetilide.45
Thallium flux assay
The thallium (Tl+) flux assay was performed using the FluxOR Potassium Ion Channel
Assay kit (cat. #F10016; Invitrogen, CA, USA) with modifications as outlined by Huang et
al.45 Briefly, hERG-expressing HEK-293 cells described above, were plated in 384-well
plates, loaded with Tl+-sensitive FluxOR reagent, and incubated with AZA for 15 min prior
to Tl+ flux across hERG channels via stimulation with a K+/Tl+-containing solution.
Fluorescence intensity at 490/525 nm (ex./em.) of each well was simultaneously monitored
using the FLIPR Tetra (MDS Analytical Technologies, Sunnyvale, CA, USA) with
Twiner et al. Page 5













ScreenWorks 2.9 software. Terfenadine was used as a positive control. Data are expressed
as Tl+ flux as determined from the initial slope of the curve following hERG channel
stimulation. All data are presented as means ± SEM of three replicate wells. IC50 and 95%
confidence interval determinations were calculated using four parameter, non-linear
regression analysis (GraphPad Prism, ver. 5.0c, CA, USA).
Results
AZA1, AZA2, and AZA3 block hERG channel current in transfected mammalian cells
Voltage clamped HEK-293 cells stably expressing hERG channels were exposed to various
concentrations of AZA1, AZA2, and AZA3 (0.064 - 1.9 μM) and hERG currents were
monitored while voltage was adjusted. Representative traces and replicated experimental
data illustrate that hERG currents were inhibited by AZA1 in a concentration-dependent
manner with a maximum inhibition of 79.5 ± 1.8% (mean ± SEM, n = 3) elicited by 1.9 μM
AZA1 (Figure 2). As determined by patch clamp experiments, the AZA1 IC50 value was
0.84 μM (Table 1). Similarly, AZA2 and AZA3 caused nearly identical concentration-
dependent inhibition of hERG currents (Figure 2B; representative traces not shown).
Maximal inhibition by AZA2 and AZA3 (1.9 μM) was 87.3 ± 0.95% and 79.7 ± 1.6% with
IC50 values of 0.64 μM and 0.84 μM; respectively. Relative potencies (relative to AZA1)
are: AZA2 > AZA3 = AZA1. Terfenadine, a well-known inhibitor of hERG channels,
elicited concentration-dependent inhibition of hERG currents (data not shown) with an IC50
of 0.019 μM (Table 1).
AZA1 blocks hERG1 channels heterologously expressed in oocytes
The mechanisms of AZA1 induced inhibition of hERG1 channels were studied in greater
detail using Xenopus laevis oocytes. WT hERG1 channel currents measured in oocytes were
slightly less sensitive to AZA1 than currents in HEK-293 cells, but had similar inhibitory
effects to those determined by binding studies in these cells described below. At a saturating
concentration (10 μM), AZA1 reduced the peak outward hERG1 current measured at –10
mV in oocytes to 19.0 ± 2.4 % of control (n = 6). The onset of hERG1 channel block in
oocytes by 10 μM AZA1 developed exponentially with a time constant of 1.5 min (Figure
3A and B). The effect of 10 μM AZA1 on the peak outward hERG1 currents (Ipeak) elicited
during pulses to a range of test voltages was determined. Steady-state changes in current
magnitude were observed after 5 - 8 min. Representative currents are shown in Figure 3C
(control) and 3D (5 min AZA1) and I-Vt relationships are plotted in Figure 3E. Ipeak was
reduced at all potentials. AZA1 did not alter the voltage dependence of rectification (Figure
3C, open triangles), indicating that it had no effect on the voltage dependence of hERG
channel inactivation. The voltage dependence of channel activation was determined by
plotting the normalized peak tail currents measured at –70 mV as a function of Vt (Figure
3F). AZA1 reduced Itail at all voltages and inhibited peak Itail by 75 ± 2% (n = 6), but did
not significantly alter the V0.5 or slope factor of the G-Vt curve determined using 2-s
activating pulses. AZA1 caused a modest acceleration in the rate of current deactivation. At
–70 mV, tail currents decayed with a bi-exponential time course with time constants of 249
± 8 ms and 1003 ± 57 ms under control conditions and 205 ± 17 ms and 745 ± 44 ms in the
presence of AZA1 (n = 6). The relative amplitude of the slow component of deactivation
was slightly reduced by AZA1 from 0.80 ± 0.02 to 0.72 ± 0.02.
Channel state dependent block by AZA1
To determine if AZA1 inhibition of hERG1 current depends on the state of the channel, we
compared the time-course of currents recorded during single test pulses applied in the
absence of AZA1 and again after a prolonged pulse-free period of AZA1 exposure. Control
current was first activated with a very long (37.8 s) pulse to 0 mV (Figure 4). AZA1 (10
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μM) was then added to the recording chamber and the oocyte was held at –70 mV without
pulsing to keep channels in a closed state for 4 min. At the end of the 4 min incubation, a
second long pulse to 0 mV was applied. Current traces for the two test pulses are
superimposed in Figure 4A for the complete pulse, and in Figure 4B for the initial 1.35 s of
the pulse. AZA1 had a minimal effect on current during the initial 0.5 s of the pulse;
afterwards inhibition developed gradually during the long pulse and neared completion by
the end of the pulse. To more clearly illustrate the time-dependent development of block by
AZA1, the current trace recorded in the presence of AZA1 was divided by the control
current trace and the resulting ratio (IAZA1/Icontrol) plotted as a function of time in Figure
4C. The ratio IAZA1/Icontrol was initially 1.0 (indicating no closed state block), decayed with
a bi-exponential time course and the extrapolated steady state ratio was 0.19. Thus, the
amount of current was reduced to 19% of control during a single long pulse to 0 mV, similar
to the average inhibition observed after 5-8 min of continual pulsing (Figure 4E). These
findings suggest that AZA1 preferentially blocks the open state of hERG1 channels.
Mutation of F656 in S6 segment of hERG1 attenuates block by AZA1
Almost all compounds that block the open state of hERG1 channels appear to interact with a
few residues in the S6 segment whose side chains face towards the central cavity.41, 47 Two
of the most commonly recognized molecular determinants of hERG1 channel block are
Phe656 and Tyr652 in S6; mutations in these residues have been shown to attenuate block
by many drugs.39-41 Therefore, we determined if mutation of either one of these residues
affected block by AZA1. F656T hERG1 channels were insensitive to 10 μM AZA1 at test
potentials negative to -20 mV (Figure 5A and B). At test potentials greater than -20 mV,
currents were slightly inhibited (e.g., peak Itail reduced by 7 ± 1%; n = 5). Y652A hERG1
channel currents were inhibited by 10 μM AZA1 at all test potentials (Figure 5C) with 76 ±
3% (n = 5) block of peak Itail (Figure 5D), similar to the block observed for WT hERG1
channels. AZA1 had no effect on the voltage dependence of F656T hERG1 channel
activation (Figure 5B), but shifted the V0.5 for activation of Y652A hERG1 channels by -5
mV (Figure 5D). Together the findings of reduced sensitivity of F656T hERG1 channels to
block by AZA1 and the time-dependent inhibition of current following a pulse-free
incubation with AZA1 (Figure 4) indicate that AZA1 is an open channel blocker.
AZA1 is a weak blocker of human EAG1 channels
To determine the channel specificity of AZA1, we examined the effect of 10 μM AZA1 on
hEAG1 channels heterologously expressed in oocytes. AZA1 slightly reduced hEAG1
currents at all test potentials examined (Figure 6A-C). At a test potential of +40 mV, AZA1
blocked hEAG1 current by 15 ± 0.8% (n = 4). AZA1 did not alter the voltage dependence of
channel activation (Figure 6D). Thus, AZA1 is a more potent blocker of hERG1 than
hEAG1 K+ channels.
AZA1, AZA2, and AZA3 bind to hERG channels
Membrane preparations from HEK-293 cells stably expressing hERG channels were used
for binding assays. Various concentrations of AZA1, AZA2, and AZA3 (0.001 to 10 μM)
were tested and each AZA analog was found to inhibit binding of radiolabeled dofetilide, a
known hERG inhibitor, in a concentration-dependent manner (Figure 7). The amount of
bound [3H]dofetilide is expressed as disintegrations per minute (dpm) (mean ± SEM) per
well. Relative to vehicle controls, hERG binding by AZA1, AZA2, and AZA3 (10 μM) was
reduced to 19.7 ± 1.4% (n = 2), 22.3 ± 1.0% (n = 3), and 29.3 ± 1.6% (n = 3) with IC50
values of 2.1 μM, 2.6 μM, and 6.6 μM; respectively (Table 1). Similarly, Ki values (with
95% confidence intervals) were 2.9 (1.3 - 6.6) μM, 3.6 (1.9 – 6.9) μM, and 8.3 (3.5 – 20)
μM, respectively. As such, there were no statistical differences in the potencies of the three
analogues (AZA1 = AZA2 = AZA3). Dofetilide, a well-known inhibitor of hERG channels,
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elicited concentration-dependent inhibition of hERG binding (data not shown) with an IC50
of 8.8 nM (Table 1).
AZA1, AZA2, and AZA3 inhibit thallium flux through the hERG channel
The flux of thallium (Tl+) through hERG channels was monitored in the presence and
absence of AZA1, AZA2, and AZA3 (0.001 to 30 μM). Each analog of AZA inhibited the
flux of thallium in a concentration-dependent manner (Figure 8). All data (mean ± SEM, n =
3) are expressed as the Tl+ flux as determined from the initial slope of the curve following
the addition of stimulation solution. Relative to vehicle controls, thallium flux via the hERG
was reduced by AZA1, AZA2, and AZA3 (30 μM) to 10.7 ± 0.56%, 9.6 ± 0.79%, and 16.6
± 0.50% with IC50 values of 4.2 μM, 5.1 μM, and 6.2 μM; respectively (Table 1). As such,
there were no significant potency differences between the AZA analogues (AZA1 = AZA2
= AZA3). Terfenadine elicited a concentration-dependent inhibition of Tl+ flux (data not
shown) with an IC50 of 8.4 μM (Table 1).
Discussion
Azaspiracids are potent algal toxins that have resulted in multiple human intoxication events
in Europe and the United States.4, 5 Due to the growing food safety concerns related to this
human health threat, many investigators have focused on elucidation of the molecular
target(s) for this toxin class. However, despite these efforts, no specific target has been
identified. For the first time, we present conclusive evidence that the AZA toxins are a new
class of hERG K+ channel inhibitors.
A wide range of drugs (and toxins) have been shown to inhibit hERG1 currents and in-depth
studies indicate that most of these compounds block K+ conductance by binding to a
canonical site and plugging the central cavity that is formed by the four S6 segments of the
homotetrameric channel.48 The side-chains of two aromatic residues (Y652 and F656)
located in each of the four S6 segments of hERG1 face towards the central cavity and are
commonly involved with hydrophobic and/or π-stacking interactions with drugs that bind to
the central cavity.39-41, 47, 49 Similar to AZA1 (C47H71NO12), the macrolide antibiotic
erythromycin (C37H67NO13) also blocks hERG1 rapidly in an open-state dependent manner
and analysis of mutant channels and molecular modeling indicate that it interacts with
phenylalanine reside at position 656 but not with tyrosine reside at position 652.50 AZA1
and erythromycin have molecular weights of 842 and 733, respectively and are much larger
than the vast majority of drugs known to block hERG1 channels. Although Y652 is located
only a single helical turn above F656 on S6, it is positioned further into the central cavity
and may be beyond reach of compounds as large as AZA1 and erythromycin. Thus, while
both AZA1 and erythromycin are open state-dependent blockers of hERG1, it seems their
large size precludes their access into the deep interior of the central cavity. We propose that
AZA1 physically blocks the K+ conductance pathway of hERG1 channels by occluding the
cytoplasmic mouth of the open pore. Pore block at this site might also explain why AZA1
does not appreciably alter the kinetics or voltage dependence of hERG1 channel gating.
Collectively, these findings are consistent with our previous patch-clamp study using spinal
cord neuronal networks wherein we concluded that AZA1 inhibited bioelectrical activity
through a mechanism that was independent of voltage-gated sodium (Na+) or calcium (Ca2+)
currents.21 However, it should be noted that bioelectrical activity was inhibited by low
nanomolar concentrations of AZA1 whereas in the present study, much higher
concentrations were necessary (i.e., micromolar).
EAG1 channels are closely related to ERG1 channels and yet are much less sensitive to
block by AZA1. This difference in potency has been noted for most well studied hERG1
blockers and has been attributed at least in part to the orientation of the two aromatic
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residues in the S6 segment of the two channels.51 Perhaps Phe468 in hEAG1 (equivalent to
Phe656 in hERG1) is not positioned for optimum hydrophobic interaction with AZA1 when
the channels are in the open state.
Relative to AZA1, AZA2 is methylated at the C8 position (8-methyl-azaspiracid) whereas
AZA3 is demethylated at the C22 position (22-demethyl-azaspiracid) (Figure 1). Despite the
methylation differences of these three AZA analogues, there does not appear to be much
difference in relative potencies towards hERG K+ channel inhibition. Each AZA analogue
was capable of inhibiting hERG K+ channel current in transfected HEK-293 cells with IC50
values ranging between 0.64 and 0.84 μM. AZA2 was slightly more potent but the potencies
of AZA3 and AZA1 were not different. However, this same trend in relative potency was
not observed via hERG channel binding (Ki values between 2.9 and 8.3 μM) and thallium
flux where all AZA analogues were found to be of the same relative potency. In contrast, it
has been shown that there are very distinctive structure-activity relationships with respect to
the cytotoxic potencies of these same AZA analogues at much smaller concentrations (i.e.,
low nanomolar). AZA2 and AZA3 have been shown to be 8.3- and 4.5-fold more potent
than AZA1; respectively.14 These potency trends have also been corroborated in vivo via
mouse lethality,52, 53 which have formed the basis for calculating the toxic equivalence
factors (TEFs) currently used by the European Union for food safety regulation (1.8 for
AZA2 and 1.4 for AZA3).8
AZAs are known to be highly potent cytotoxic agents to all cell types tested15, 54 and have
been shown to induce apoptosis.22 Similarly, many hERG channel inhibitors are also known
inducers of apoptosis29 and can cause cytotoxicity towards a wide variety of cell lines.55, 56
Although cardiomyocytes and neurons are most sensitive, the broad distribution of hERG
channels across many cell/tissue types likely plays a role in mediating this cytotoxic
response. When administered via intraperitoneal injection to rodents, AZAs can cause a
variety of neurotoxic, immunotoxic, and hepatotoxic effects that can result in death.52, 53, 57
In fact, the very first AZA studies used contaminated shellfish extracts that were injected
into mice and caused a ‘neurotoxin-like’ response followed by death. 58, 59 This response
quite feasibly could have been via potassium channel inhibition.
In vitro, AZAs have been shown to directly enter into cells.60 When administered orally,
AZAs are systemically distributed9, 10 and can cause severe gastrointestinal degradation
followed by a variety of other effects including hepatotoxicity and immunotoxicity.11, 12
Many of the other open channel blockers of hERG (i.e., methanesulfonanilides such as
E-4031, MK-499, and dofetilide) can have a wide spectrum of toxicological effects in vivo,
but generally do not have a history of gastrointestinal side effects61, 62 despite the presence
of hERG channels in intestinal epithelial cells. In vivo exposure to mechanistically similar
hERG channel blocking compounds such as erythromycin can have profound hepatotoxic
effects63 not unlike those induced by AZAs but commonly have their most dramatic effects
on the heart, causing prolongation of cardiac action potentials,64 which may lead to a
potentially lethal form of cardiac arrhythmia called torsades-de-pointes. During a recent
mini-pig feeding study, animals were acutely administered AZA-contaminated feed (200 μg
AZAtotal/kg) and monitored over a 24 h period. Despite an absence of overt symptoms, there
were histological indications of gastrointestinal perturbations and coincident with peak
AZAtotal blood concentrations (ca. 3.2 nM at 4 h) peripheral lymphocyte differential gene
expression using DNA microarrays were suggestive of a strong inflammatory response
including markers of cardiomyopathy (unpubl. data). These preliminary findings provide the
first physiological linkage between potassium channel inhibition and AZA toxicity. As such,
future in vivo studies testing AZAs should assess potential cardiotoxic effects of these toxins
(i.e., electrocardiogram, molecular markers, etc.).
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A mechanism of action for the AZA toxin class has been sought for many years by multiple
investigators. Although we have confirmed that AZAs are low affinity hERG potassium
channel inhibitors, it is almost certain that the AZAs have other molecular targets as
discussed previously.13, 14, 19 There are discrepancies between the concentrations and
relative potencies of the AZA analogues necessary to cause cytotoxicity (sub- to low-
nanomolar with AZA2 > AZA3 > AZA1) and those that are needed to inhibit hERG channel
current (≥ 640 nM with AZA2 > AZA1 = AZA3). Similarly, in vivo toxic doses tend to be
much lower for AZAs (≤ 500 g/kg)9, 10, 52, 53 relative to many of the other known hERG
channel inhibitors (> 5 mg/kg). Finally, our previous study has shown that AZA1 is highly
cytotoxic to wild-type HEK-293 cells (EC50 values range between 2.5 and 4.6 nM)15 that do
not have hERG K+ channels. As such, these discrepancies suggest that another molecular
target(s) may be responsible for the cytotoxic effects of the AZAs.
The effects of long-term exposure of AZAs to human health are unknown. AZA1 has been
shown to be a possible carcinogen in rodents11 and a teratogen to developing fish where we
specifically noted dose-dependent bradycardia65 which has been demonstrated for several
other hERG blockers66 including erythromycin67. It is conceivable that humans consuming
AZAs via contaminated shellfish may be at risk for teratogenicity and/or torsades-de-
pointes; however, targeted diagnostic evaluation of teratogenicity and cardiac function will
be required to confirm such a response.
Conclusions
For the first time we have conclusively identified the hERG channel as a molecular target
for the AZA toxins. Through the use of voltage clamp, channel binding studies, and ion flux
assays, we have demonstrated that AZA1, AZA2, and AZA3 bind to and block potassium
current through hERG channels. AZA1 was shown to be an open state-dependent blocker of
hERG1 that interacts with F656 within the S6 transmembrane domain that forms the
channel's central pore. We propose that AZA1 physically blocks the K+ conductance
pathway of hERG1 channels by occluding the cytoplasmic mouth of the open pore.
Although AZAs block with low affinity, these findings set the stage for future studies
assessing the involvement of hERG channel blocking in AZA-induced toxicity.
Furthermore, these findings may facilitate the identification of other molecular targets and
the development of a functional channel binding bioassay that will be useful for rapid, high-
throughput screening assays of naturally contaminated seafood.
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hERG human ether-a-go-go-related gene
AZA azaspiracid
hBB hERG binding buffer
DMSO dimethyl sulfoxide
PBS phosphate buffered saline
dpm disintegrations per minute
CI confidence interval
IC50 50% inhibitory concentration
LC-MS/MS liquid chromatography-mass spectrometry/mass spectrometry
IKr rapid delayed rectifier potassium current
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Chemical structures of AZA1, AZA2, and AZA3.
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AZAs block hERG1 channels expressed in HEK-293 cells. (A) Representative patch clamp
traces of potassium ion current through hERG channels stably expressed in HEK-293 cells
in the presence of various concentrations of AZA1. (B) Concentration-dependent inhibition
of potassium ion current through hERG channels by AZA1, AZA2, and AZA3. Data (mean
± SEM; n=3) were normalized to the control (DMSO vehicle) and analyzed using non-linear
sigmoidal dose-response (variable slope). Terfenadine was used as a positive control (data
not shown). Calculated IC50 values are shown in Table 1.
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AZA1 blocks hERG1 channels expressed in Xenopus oocytes in a voltage-independent
manner. (A) Voltage clamp protocol (upper panel) and currents (lower panel) recorded
during repetitive pulsing to 0 mV. Pulse duration was 1 s and the interpulse interval was 8 s.
The initial 15 pulses were recorded in the absence of toxin; the remaining traces illustrate
the gradual reduction in current amplitude during the onset of channel block by 10 μM
AZA1. (B) Peak outward current at the end of the 1-s pulse (Ipeak) plotted as a function of
time after addition of AZA1. The onset of block developed exponentially with a time
constant (τonset) of 1.5 min. (C) and (D) Voltage clamp protocol (upper panel) and current
traces (middle and bottom panels) recorded during control conditions (C) and 7 min after
addition of 10 μM AZA1 (D) to the recording chamber. (E) Effect of AZA1 on I-Vt
relationship (n = 6). The AZA1 current amplitudes were multiplied by 5.274 and replotted
(open triangles) to facilitate comparison of the voltage-dependence of the I-V relationships
between control and AZA1 currents. AZA1 did not alter the voltage dependence of
rectification, indicating that it had no effect on the voltage dependence of hERG channel
inactivation. (F) Effect of 10 μM AZA1 on the G-Vt relationship. Normalized Itail was
plotted as a function of Vt and fitted with a Boltzmann function (smooth curves). For
control, V0.5 = -22.0 ± 0.5 mV; k = 8.1 ± 0.3. For AZA1, V0.5 = -20.7 ± 0.5 mV; k = 9.6 ±
0.3 (n = 6).
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AZA1 preferentially blocks hERG1 channels in the open state. (A) and (B) Superimposed
traces of currents recorded before (control) and after a 4 min pulse-free period of incubation
of oocyte with 10 μM AZA1. Currents were recorded in response to 37.8 s pulse to 0 from a
holding potential of -70 mV. The complete current traces are shown in panel A and the
region delineated by the dotted box (initial 1.34 s of pulse) is shown on an expanded time
scale in panel B. (C) The ratio IAZA1/Icontrol plotted as a function of time during the pulse to
0 mV. The decay of IAZA1/Icontrol with time is a direct measure of the bi-exponential onset
of current block with τfast = 2.96 s (amplitude = 0.325) and τslow = 12.66 s (amplitude =
0.433). The steady state relative current amplitude (0.192) represents the amount (19.2%) of
unblocked current. R2 for fit was 0.997.
Twiner et al. Page 18














Block of hERG1 by AZA1 is attenuated by mutation of F656 but not Y652. (A) Effect of 10
μM AZA1 on the I-Vt relationship for F656T hERG1 channels. (B) Effect of 10 μM AZA1
on the G-Vt relationship for F656T hERG1 channels. Normalized Itail was plotted as a
function of Vt and fitted with a Boltzmann function (smooth curves). For control, V0.5 =
-31.0 ± 0.2 mV; k = 7.8 ± 0.1. For AZA1, V0.5 = -32.6 ± 0.3 mV; k = 7.3 ± 0.1 (n = 5). (C)
Effect of 10 μM AZA1 on the I-Vt relationship for Y652A hERG1 channels. (D) Effect of
10 μM AZA1 on the G-Vt relationship for Y652A hERG1 channels. Normalized Itail was
plotted as a function of Vt and fitted with a Boltzmann function (smooth curves). For
control, V0.5 = -20.7 ± 0.6 mV; k = 6.4 ± 0.3. For AZA1, V0.5 = -26.0 ± 0.8 mV; k = 7.3 ±
0.4 (n = 5).
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AZA1 is a weak blocker of hEAG1 channels. (A) Voltage clamp protocol used to elicit
currents illustrated in panels B and C. (B) Control hEAG1 currents. (C) Currents recorded in
the presence of 10 μM AZA1. (D) Effect of AZA1 on the I-Vt relationship for hEAG1
channels. (E) Effect of AZA1 on the G-Vt relationship for hEAG1 channels. Normalized
Ipeak/(Vt-Erev) was plotted as a function of Vt and fitted with a Boltzmann function (smooth
curves). For control, V0.5 = 4.6 ± 0.7 mV; k = 16.3 ± 0.6. For 10 μM AZA1, V0.5 = 6.4 ±
0.9 mV; k = 15.7 ± 0.7 (n = 4).
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AZAs compete with dofetilide for hERG potassium channels. Various concentrations of
AZA1, AZA2, and AZA3 were used as competitors in a [3H]dofetilide hERG channel
binding assay. All data (mean ± SEM; n=3) were analyzed using non-linear sigmoidal dose-
response. Dofetilide was used as a positive control. Calculated IC50 values are shown in
Table 1.
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AZAs inhibit thallium flux through hERG potassium channels. Various concentrations of
AZA1, AZA2, and AZA3 were tested using the thallium (Tl+) flux assay. All data (mean ±
SEM; n=3) were analyzed using non-linear sigmoidal dose-response. Terfenadine was used
as a positive control. Calculated IC50 values are shown in Table 1.
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